FDA Approves Zycubo For Rare Menkes Disease
In a significant milestone for rare disease treatment, the United States Food and Drug Administration has approved Zycubo (copper histidinate) for the treatment of paediatric patients with Menkes disease. The approval marks the first and only authorised therapy for the condition in the United States, offering new hope for affected children and their families. Regulatory Approval and Company Background Zycubo has been approved for use in children suffering from Menkes disease, a rare and often fatal genetic disorder. The therapy has been developed by Sentynl Therapeutics Inc, which is wholly owned by Zydus Lifesciences. Sentynl acquired the drug from Cyprium Therapeutics in 2023 and subsequently advanced it through the final stages of regulatory review with the U.S. Food and Drug Administration. Clinical Development and Special Designations The approval was supported by positive results from pivotal clinical studies. During development, Zycubo received multiple regulatory designat...